Goldman Sachs Group Reiterates “CHF 109” Price Target for Novartis (VTX:NOVN)

Novartis (VTX:NOVN) has been assigned a CHF 109 target price by Goldman Sachs Group in a report released on Wednesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock.

Several other equities research analysts have also commented on the stock. Jefferies Financial Group set a CHF 105 price objective on shares of Novartis and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Kepler Capital Markets set a CHF 86 price objective on shares of Novartis and gave the stock a “neutral” rating in a research note on Tuesday, July 21st. JPMorgan Chase & Co. set a CHF 82 target price on shares of Novartis and gave the stock a “sell” rating in a research note on Tuesday, August 18th. UBS Group set a CHF 98 target price on shares of Novartis and gave the stock a “buy” rating in a research note on Thursday, September 10th. Finally, Oddo Bhf set a CHF 97 target price on shares of Novartis and gave the stock a “buy” rating in a research note on Monday, June 22nd. Two analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of CHF 94.31.

Novartis has a 52-week low of CHF 72.45 and a 52-week high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

See Also: What is the CAC 40 Index

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.